Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. (ALNA): 2 pipeline candidates · ~6 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.3 months
D/E 3.76 · 0% dilution
Lead: Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for Allena Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$6.6M
Quarterly Burn
$4.6M
Runway
6.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| alln-346 | Preclinical |
| reloxaliase | Phase 3 |
Frequently asked questions
How many drug candidates are in Allena Pharmaceuticals, Inc.'s pipeline?
Allena Pharmaceuticals, Inc. (ALNA) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Allena Pharmaceuticals, Inc.'s lead drug candidate?
Allena Pharmaceuticals, Inc.'s most advanced tracked candidate is alln-346 (Preclinical) for hyperuricemia and gout in the setting of advanced CKD.
What is Allena Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Allena Pharmaceuticals, Inc. has approximately 6.3 months of cash runway.
Who is the CEO of Allena Pharmaceuticals, Inc.?
Louis Brenner, M.D. is the chief executive officer of Allena Pharmaceuticals, Inc. (ALNA).
Get the full picture on Allena Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.